Microbion Corporation, a US-based clinical-stage pharmaceutical company, announced on Thursday that it has started a Phase two, randomised, controlled study to evaluate the safety and efficacy of topical pravibismane to treat patients with moderate infections of chronic diabetic foot ulcers (DFU).
The company is planning to enrol 54 subjects with chronic moderate DFU infections in the present phase two exploratory study comparing 12 weeks of pravibismane treatment plus standard of care versus standard of care treatment alone. The study's main objective is to assess the safety and tolerability of topical pravibismane, while the secondary objective is to explore key signals of efficacy demonstrated in an earlier study. These efficacy endpoints include complete wound closure, reduction in the number and extent of amputations, reduction in wound size, and resolution of infection. This study is being conducted at select wound care sites in Texas and California, and potentially other US sites in the future. More information about the study can be found on Clinicaltrials.gov (identifier number: NCT05174806).
Pravibismane is the first in a new class of anti-infective drugs demonstrating broad-spectrum potency against a wide range of multidrug-resistant bacteria, and biofilms ubiquitous in DFU infections and widely recognised as one of the leading causes of treatment failure. Topical pravibismane has been safe and well-tolerated in five clinical studies involving over 325 human subjects.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes